Hengrui Pharma Signs Exclusive License With Novo For Once-Weekly Oral GLP-1/GIP Agonist HRS-1596, Featuring $300M Upfront In Up To $2.6B Deal

Benzinga Newsdesk www.benzinga.com Positive 59.1%

Neg 0% Neu 0% Pos 59.1%

HRS-1596 is a phase I-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing
Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, as well as potential sales royalties

Comments

No comments yet. Be the first!